The Summit County Board of Health meeting on September 11, 2023, focused on the upcoming respiratory syncytial virus (RSV) season and the introduction of a new monoclonal antibody treatment aimed at high-risk populations. Health officials discussed the anticipated increase in RSV cases as the season approaches, particularly in Florida and the Southeast, which typically signal the start of the RSV season.

Officials noted that this year is projected to see case counts closer to pre-COVID levels, influenced by the presence of many children who had limited exposure to RSV during the pandemic. The new monoclonal antibody treatment, which is being referred to as a vaccine for familiarity, is expected to be available this fall. It is specifically targeted at adults aged 60 and over with high-risk factors, as well as children under 19 months entering their first or second RSV season.

The treatment will not be an annual vaccine like the flu shot, and its administration will involve shared decision-making between physicians and patients or parents. Health officials emphasized that while the treatment is available for older adults, it is not intended for all individuals over 60, but rather those with specific health risks.

The meeting also touched on the challenges faced during the previous winter, which was described as particularly severe for vulnerable populations. The Board of Health is closely monitoring the situation as the new treatment becomes available, aiming to mitigate the impact of RSV this season.